PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Open Access
- 1 January 2015
- journal article
- review article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 5 (12), 1388-1401
- https://doi.org/10.7150/thno.13348
Abstract
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for these purposes. However, its application is limited to patients with high PSA levels and Gleason scores. Prostate-specific membrane antigen (PSMA) is a promising new target for specific imaging of PCa, because it is upregulated in the majority of PCa. Moreover, PSMA can serve as a target for therapeutic applications. Currently, several small-molecule PSMA ligands with excellent in vivo tumor targeting characteristics are being investigated for their potential in theranostic applications in PCa. Here, a review of the recent developments in PSMA-based diagnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided.Keywords
This publication has 77 references indexed in Scilit:
- 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate CancerJournal of Nuclear Medicine, 2015
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate CancerMolecular Imaging & Biology, 2015
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and TherapyJournal of Nuclear Medicine, 2015
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate CancerJournal of Nuclear Medicine, 2014
- Prospects in radionuclide imaging of prostate cancerThe Prostate, 2011
- 68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate CancerJournal of Medicinal Chemistry, 2010
- Nuclear Medicine Studies of the Prostate, Testes, and BladderSeminars in Nuclear Medicine, 2006
- Constitutive and antibody-induced internalization of prostate-specific membrane antigen.1998
- Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.1987